YBD ameliorates rheumatoid arthritis by suppressing the JAK/STAT signaling pathway and associated inflammatory responses, thereby providing a mechanistic basis for its potential therapeutic application in rheumatoid arthritis.
Abstract
Objective
To investigate the therapeutic effects of Yibi Decoction (YBD) in rheumatoid arthritis (RA) and to elucidate the underlying mechanisms, with a particular focus on the JAK/STAT signaling pathway.
Methods
Network pharmacology analysis was employed to predict the bioactive compounds and potential therapeutic targets of Yibi Decoction. A collagen-induced arthritis (CIA) rat model was established to validate the predicted effects in vivo. Western blotting, enzyme-linked immunosorbent assay (ELISA), and histopathological analyses were conducted to evaluate alterations in joint tissues and serum inflammatory biomarkers.
Results
Network pharmacology analysis identified 128 bioactive components in YBD, among which quercetin and luteolin were predicted to be key active compounds. In CIA rats, YBD treatment significantly downregulated the expression of IL-6, IL-17, IL-23, JAK2, and STAT3 in ankle joint tissues (P < 0.05), and markedly reduced serum levels of anti-cyclic citrullinated peptide (anti-CCP) antibodies and rheumatoid factor (P < 0.05). In parallel, the arthritis index was significantly decreased, and histopathological examination revealed substantial attenuation of synovial hyperplasia and cartilage destruction.
Discussion
These findings suggest that YBD exerts anti-rheumatoid arthritis effects through a multi-component, multi-target regulatory mechanism involving inhibition of the JAK/STAT signaling pathway. Quercetin and luteolin may contribute to these effects by suppressing pro-inflammatory cytokine production and ameliorating joint pathological changes.
Conclusion
YBD ameliorates rheumatoid arthritis by suppressing the JAK/STAT signaling pathway and associated inflammatory responses, thereby providing a mechanistic basis for its potential therapeutic application in rheumatoid arthritis.
An integrated pharmacological framework explaining how ZDQHM exerts its effects via regulation of the IL-17A/IL-17RA/Act1 axis is provided, offering mechanistic insights and experimental support for TCM in AS therapy.
Dan Liu, Yanrong Wei, Zi-Jing Ge et al.· Biomedical chromotography· 0 citations
CNZP exhibits significant therapeutic effects on RA, potentially by downregulating NOS1 expression and subsequently correcting the metabolic imbalance of L-arginine, and this preclinical study provides mechanistic evidence for the anti-RA effect of CNZP.
Zhi-Qiang Li, Liang Cao, Jia-Jia Wang et al.· Clinical Rheumatology· 0 citations
This work elucidated the anti-RA mechanism of S. inappendiculata: eight xanthones acted on the PI3K/AKT/mTOR/HIF-1α/GSK-3β axis to induce M1 macrophage apoptosis, validating the integrated approach and laying groundwork for RA treatment and natural product research.
Xuan Chen, Bing-Ru Fan, Ting Wang et al.· Current Computer - Aided Dru...· 0 citations
This study demonstrates that triptolide alleviates RA through NR1D1‐mediated inhibition of JAK1/STAT3 signaling, thereby revealing the NR1D1/JAK1/STAT3 axis as a potential therapeutic target for RA.
Conglin Ren, Ming-Shuang Li, Caijian He et al.· Mediators of Inflammation· 0 citations
It is suggested that JQR exerted therapeutic effects on AGA via the coordinated regulation of multiple components and targets through the Ras/Raf/MEK/ERK signaling pathway.
Nan-Fei Zhu, Yun-Xiang Cao, Amin Wang et al.· Histology and Histopathology· 0 citations
Psoriasis is a chronic immune-mediated skin disease characterized by strong genetic susceptibility and autoimmune components. Identifying lead compounds from natural products for psoriasis has been proposed as a promising therapeutic strategy. Citri Reticulatae Pericarpium (CRP) is a traditional Chinese medicine materi...
Qing Liu, Jing Liu, Zi-Ren Wang et al.· International Immunopharmaco...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.